Diabetes

NMDAM Celebrating 25 Years with - ONE VOICE, ONE VISION ...TO HEAL AND SAVE LIVES

Thursday, August 5, 2021 - 9:48pm

The need for organ donation and transplantation, especially kidney, is more pronounced in minority communities.

Key Points: 
  • The need for organ donation and transplantation, especially kidney, is more pronounced in minority communities.
  • Our voices are united to address the number one problem in transplantation: the gap between the demand for organ transplants and supply of donated organs.
  • The waiting list currently stands at more than 100,000 with more than 60% representing racial and ethnic minorities.
  • Please use hashtag #NMDAM when sharing and supporting National Minority Donor Awareness messages and information on social media.

New Low-Glycemic Ayurvedic Protein Bars Coming to America

Thursday, August 5, 2021 - 7:58pm

Our protein bars contain Ashwagandha, which is known as a stress buster and energy booster.

Key Points: 
  • Our protein bars contain Ashwagandha, which is known as a stress buster and energy booster.
  • Atmabala plans to roll out two protein bars later this year: Chocolate Almond and Almond Coconut.
  • Shanmugam said he and his partner, Hema Saran, had been considering developing several healthy products, but COVID-19 helped them focus on protein bars.
  • We know that diabetes is at epidemic levels in the United States, which is why low glycemic protein bars are so important, he said.

Coalition of Leading Health Professionals and Advocates Calls on Congress to Act Now to Strengthen Medicare by Adding Dental Coverage

Thursday, August 5, 2021 - 4:45pm

Medicare does not currently include coverage for dental health services as a standard benefit.

Key Points: 
  • Medicare does not currently include coverage for dental health services as a standard benefit.
  • Of the 60 million older adults and individuals with disabilities who receive Medicare benefits, 67% of them37 milliondo not have dental coverage.
  • Poor oral health is linked with cardiovascular disease, diabetes, cancer, and pneumonia, the risk of which increases among older adults.
  • CareQuest Institute for Oral Health is a national nonprofit championing a more equitable future where every person can reach their full potential through excellent health.

OXURION to Participate in Upcoming Investor Meetings

Thursday, August 5, 2021 - 4:45pm

Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020.

Key Points: 
  • Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in 2020.
  • Oxurion is currently conducting a Phase 2 clinical trial evaluating THR-687 in patients with DME.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

Founders of Heal Raise $3.8 Million for New Health Tech Start-Up: HeyRenee

Thursday, August 5, 2021 - 1:05pm

HeyRenee is using seed proceeds to curate digital health partners, build a world-class team of product & engineering leaders, and win early customers.

Key Points: 
  • HeyRenee is using seed proceeds to curate digital health partners, build a world-class team of product & engineering leaders, and win early customers.
  • However, the true potential of the digital health revolution is to transform care for the neediest amongst us.
  • We're in the first inning of realizing the true potential of the digital transformation of American healthcare, said Nick Desai, co-founder of HeyRenee.
  • HeyRenee is the personal health concierge, everyone, especially those managing chronic illnesses and conditions, has wanted and needed.

DayTwo Announces New CEO and Raises $37 Million For Expansion of Chronic Disease Solutions

Thursday, August 5, 2021 - 1:15pm

The company also announced $37 million in new funding to accelerate its expansion of chronic disease solutions for employers, health plans, and health systems.

Key Points: 
  • The company also announced $37 million in new funding to accelerate its expansion of chronic disease solutions for employers, health plans, and health systems.
  • DayTwos proven solutions drive significant positive health outcomes for the more than 122 million adults in the U.S. with diabetes and prediabetes.
  • Im thrilled to be joining a unique and innovative company that is helping people live healthier lives and manage their chronic conditions, said David Henderson, CEO of DayTwo.
  • To learn more about DayTwo and its solutions for chronic disease, visit www.daytwo.com .

Modern Vascular Brings Innovative Treatments to Prevent Unnecessary Limb Loss to Kansas City

Thursday, August 5, 2021 - 1:02pm

Dr. Correa, a long-time presence in the Kansas City medical community as a vascular surgeon, completed his general and surgical fellowship training at Saint Louis University.

Key Points: 
  • Dr. Correa, a long-time presence in the Kansas City medical community as a vascular surgeon, completed his general and surgical fellowship training at Saint Louis University.
  • Modern Vascular clinics specialize in the treatment of peripheral artery disease (PAD) through below-the-knee and below-the-ankle and pedal endovascular arterial reconstruction.
  • Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients.
  • Modern Vascular now operates and manages sixteen clinics across AZ, CO, IN, KS, MO, MS, NM, TX, VA. For more information, visit www.ModernVascular.com .

Allergies in Primary Care: A Study of the Allergy Management Evaluation Tool Published on Consultant360 Specialty Network

Thursday, August 5, 2021 - 12:59pm

West Palm Beach, FL, Aug. 05, 2021 (GLOBE NEWSWIRE) -- USA Equities Corp. (OTCQB: USAQ), a company focused on providing clinicians with tools to profit from value-based healthcare solutions through the use of modern digital technologies, today announced the publication on Consultant360 Specialty Network of its research paper entitled “Allergies in Primary Care: A Study of the Allergy Management Evaluation Tool.” Consultant360.com is a direct-to-practitioner website designed to provide timely and relevant information to clinicians as to how to profitably improve patient care.

Key Points: 
  • The recently published Allergies in Primary Care: A Study of the Allergy Management Evaluation Tool focuses on clinician and patient results and feedback from the use of the Companys Allergy Management Evaluation (AME) tool.
  • The AME software tool was developed to capture patient self-reporting information accurately, reliably and with ease of use.
  • Results from the study demonstrated that:
    The results from this study highlight the attractiveness of our targeted solutions and strong value proposition.
  • The Companys products and information service portfolio are directed toward prevention, early detection, management and reversal of allergies, cardio-metabolic and other chronic diseases.

BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease

Thursday, August 5, 2021 - 1:00pm

The NM101 study ( NCT04669028 ) is a potentially pivotal Phase 3, randomized, double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD.

Key Points: 
  • The NM101 study ( NCT04669028 ) is a potentially pivotal Phase 3, randomized, double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD.
  • The mechanistic basis for the study design was recently published in a peer-reviewed article in Neurodegenerative Disease Management ( https://doi.org/10.2217/nmt-2021-0022 ).
  • The Company is conducting a Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028).
  • A Phase 2 study of NE3107 in Parkinsons Disease is planned for later this year, and related compounds have additional potential to treat certain cancers.